Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease: a single-center retrospective case series.

Acta gastro-enterologica Belgica·2026
Same author

Prognostic superiority of International Prognostic Index over [<sup>18</sup>F]FDG PET/CT volumetric parameters in post-transplant lymphoproliferative disorder.

EJNMMI research·2021
Same author

Semi-Quantitative Characterization of Post-Transplant Lymphoproliferative Disorder Morphological Subtypes with [<sup>18</sup>F]FDG PET/CT.

Journal of clinical medicine·2021
Same author

Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.

Annals of hematology·2019
Same author

Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis.

Critical reviews in oncology/hematology·2018
Same author

Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Related Experiment Video

Updated: May 13, 2026

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
08:44

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant

J Morscio1, D Dierickx, J F Ferreiro

  • 1Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium.

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
|March 16, 2013
PubMed
Summary

Epstein-Barr Virus (EBV) status, not immune status, determines the biological differences in posttransplant diffuse large B cell lymphoma (PT-DLBCL). EBV(+) PT-DLBCL exhibits a distinct viral response signature and inflammatory profile.

More Related Videos

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

Related Experiment Videos

Last Updated: May 13, 2026

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
08:44

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Posttransplant lymphoproliferative disorder (PTLD) is a serious risk for transplant recipients, often presenting as Epstein-Barr Virus (EBV)-associated diffuse large B cell lymphoma (DLBCL).
  • Understanding the biological distinctions between EBV-positive and EBV-negative PT-DLBCL is crucial for targeted therapies.

Purpose of the Study:

  • To characterize the clinicopathological and molecular-genetic features of PT-DLBCL.
  • To determine if EBV(+) and EBV(-) PT-DLBCL exhibit significant biological differences.

Main Methods:

  • Gene expression profiling was conducted on 48 DLBCL samples (33 PT-DLBCL, 15 immunocompetent DLBCL).
  • Unsupervised hierarchical analysis and inference analysis were used to identify molecular signatures and immune responses.

Main Results:

  • Hierarchical analysis revealed sample clustering based on EBV status, not immune status.
  • EBV(+) PT-DLBCL displayed a unique viral response signature, differentiating it from EBV(-) PT-DLBCL and immunocompetent DLBCL.
  • A broad EBV latency profile (LMP1+/EBNA2+) was linked to increased inflammatory responses, and innate/tolerogenic immune responses were implicated in EBV(+) PT-DLBCL.

Conclusions:

  • EBV status is the primary determinant in the pathogenesis of EBV(+) PT-DLBCL.
  • EBV(+) PT-DLBCL has distinct molecular and immunological characteristics compared to EBV(-) DLBCL.